Key Investor Signals
Secured a UK dementia pre-screening contract
A-Eye Scope was selected for Innovate UK’s SBRI programme supporting dementia biomarker tools. The pre-procurement contract supports development of a scalable point-of-care pre-screening system.
Co-founder built an NHS referral system used at scale
Co-founder James Wood previously founded Data Transparency, whose electronic clinical-referral system handled more than 200,000 patient transfers for the NHS.
Joined Cambridge Enterprise’s life-sciences portfolio
Cambridge Enterprise identified CVT as a life-sciences portfolio company supported by its venture arm after the team completed the University of Cambridge’s START 1.0 accelerator.
Team
Andrew Kadis
Co-founder & CEO
- Earned a PhD in engineering at the University of Cambridge before developing connected medical-device technologies.
- Managed research and development projects for Boston Scientific and GE Healthcare as a technology consultant.
- Contributed to connected health products, including wearable fitness trackers and a smart inhaler, over a 15-year career.
James Wood
Co-founder
- Founded Data Transparency, whose NHS electronic-referral system handled more than 200,000 patient transfers.
- Served as Head of Strategy and Machine Learning at PPAYA, applying AI to renewable-energy trading.
- Studied physics at Oxford and attended Columbia University’s MBA programme, combining technical and commercial training.
Milad Alemohammad
Co-founder
- Developed optical and electronic systems across biomedical imaging, telecommunications and signal-processing applications.
- Worked as an optical engineer at MindPortal on non-invasive neural-interface imaging and signal processing.
- Conducted biomedical-imaging and ultrafast signal-processing research at Johns Hopkins University.
Product
A-Eye Scope combines retinal-imaging hardware with a software platform that analyzes ocular biomarkers. Its machine-learning approach combines extracted vascular features with non-imaging inputs, such as cognitive-test scores, to support Alzheimer’s risk stratification.
Capturing retinal images
The team is developing a non-invasive retinal-imaging headset intended for use with limited operator training. Automated capture is designed to make consistent eye-image collection practical outside specialist imaging departments.
Combining imaging and clinical inputs
Machine-learning models analyze vascular features extracted from the retina alongside information such as cognitive-test scores. The resulting measurements are intended to support clinicians’ interpretation at early stages of impairment.
Managing images and analysis
The integrated platform supports remote image capture, storage and execution of analysis algorithms. It is designed for clinicians and researchers, including teams developing their own models from retinal-image data.
Market Overview
Cambridge Vision Technology addresses retinal-imaging equipment and diagnostic analysis software for clinical screening. Eye-care providers already purchase fundus cameras, while primary-care and research settings are adopting image-analysis tools. Alzheimer’s screening is a proposed use within this broader equipment and software ecosystem.
Purchasers need practical image acquisition, interpretable results and integration with referral workflows. The established retinal-camera market and emerging AI-enabled ophthalmic-device market provide commercial benchmarks for the platform, while use in Alzheimer’s assessment requires disease-specific clinical evidence.
Global fundus-camera revenue was estimated at $370.6M in 2024.
Global fundus-camera revenue is forecast to grow 6.4% annually from 2025 to 2030.
Non-mydriatic cameras accounted for 49.4% of global fundus-camera revenue in 2024.
US AI-enabled ophthalmic diagnostic-device revenue was estimated at $64.3M in 2025.
Comparable Outcomes
Optos
Optos developed retinal-imaging systems for eye-care professionals, enabling widefield views used in screening and clinical assessment. Nikon’s acquisition became effective in May 2015.
Avid Radiopharmaceuticals
Developed PET imaging agents designed to detect amyloid plaques associated with Alzheimer's disease. Eli Lilly completed the acquisition in December 2010.
Interested in More Startups Like Cambridge Vision Technology?
Get a curated pipeline of healthcare and life sciences startups aligned with your investment thesis.
Sources
This profile was built from public company materials, ecosystem sources, market references, and professional profiles.